MARKET WIREReuters • 4h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
Why DARE Stock advanced +0.22% Today — RQD Quant Desk Flash
$0.68 +0.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.68
Dare Bioscience Inc. (DARE) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $13.4M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on DARE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is DARE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Dare Bioscience Inc. (NASDAQ: DARE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $0.68 (+0.22% 1D, market cap $13.4M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DARE ranks #523 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does DARE compare to BFRI and RKTO in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DARE carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 71.3%, and ROIC of -35.0%. By comparison, BFRI (Biofrontera Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $13.8M) and RKTO (Rocket One Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $12.8M). Among the 5-stock peer group, DARE leads on earnings multiple (N/A) while DARE leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for DARE?
▼
Per DARE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001401914), Dare Bioscience Inc. generated $1.0M in revenue (+10429.4% YoY), -$13.4M in net income, and -$10.3M in free cash flow against $32.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.68 (-0.15%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-5.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DARE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY DARE SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (30% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (25% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$0.77-5.2% Next Q
52
Q2 (-2Q)Grade D$0.73-11% Next Q
49
Q3 (-1Q)Grade D$0.65+4.6% Next Q
47
CurrentGrade D$0.68-6.5% Hist 90D α
44
Trajectory: C- (52) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a DARE Turnaround Squeeze
While DARE currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.75) and Max Pain ($0.71) forces dealer call-delta covering toward $3.97.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $DARE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DARE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why DARE Stock advanced +0.22% Today — RQD Quant Desk Flash
Dare Bioscience Inc. (DARE) advanced +0.22% to $0.68, trading at 2% of its 52-week range ($0.63 – $3.78). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.63 – $3.78) with RSI-14 at 42.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.68 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 71.3% gross margin and $0 annual free cash flow.
Live DARE Headlines & Catalysts
MARKET WIREReuters • 4h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
MARKET WIREReuters • 5h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 7h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 9h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 9h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 10h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 12h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DARE)
- ✓Walkthrough of DARE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
DARE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -70.18%▲ RESISTANCE BREAKOUT
2026-10-30O $0.70H $0.70L $0.67C $0.68VOL 651.5K
RES: $0.56SUP: $0.62SMA50: $0.75SMA200: $1.58
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
DARE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on DARE today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for DARE. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DARE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DARE)
Health Care Rank #523 of 1016
⚔️ BFRI vs DARE Full Matrix →
1. Head-to-Head Health Care Peer Comparison (DARE vs. BFRI, RKTO, ALLR, LPCN)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Dare Bioscience Inc. (DARE) ranks #523 by composite RQD confidence (44/100, grade D) and #867 by equity capitalization ($13.4M). Within this direct 5-issuer industry benchmark cohort, DARE leads on earnings valuation at N/A trailing P/E, while DARE leads on capital efficiency and profitability with -35.0% ROIC and 71.3% gross margin. DARE currently leads its immediate peer cohort in composite quantitative strength at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DARE
ACTIVE
Dare Bioscience Inc. | D | 44/100 | — | 71.3% | -35.0% | +0.22% | $13.4M | Benchmark Subject |
| BFRI Biofrontera Inc. | D- | 40/100 | — | — | -35.0% | +5.09% | $13.8M | /bfri-vs-dare → |
| RKTO Rocket One Inc. | D | 44/100 | — | — | -35.0% | -4.96% | $12.8M | /rkto-vs-dare → |
| ALLR Allarity Therapeutics Inc. | D- | 38/100 | — | — | -35.0% | -6.32% | $14.2M | /allr-vs-dare → |
| LPCN Lipocine Inc. | D- | 37/100 | — | — | -35.0% | +0.66% | $12.5M | /lpcn-vs-dare → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001401914In its most recent audited fiscal period (FY2025, filed 2025-12-31), Dare Bioscience Inc. (DARE) reported GAAP revenue of $1.0M (+10429.4% vs. FY2024 revenue of $9.8K , and -63.3% cumulative change since FY2023) , GAAP net income of -$13.4M, operating cash flow of -$9.9M, and free cash flow of -$10.3M (-309.6% YoY). On the balance sheet, DARE closed FY2025 with $32.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.0M | -$13.4M | -$9.9M | -$10.3M | $32.5M | — |
| FY2024 (FY) | 2024-12-31 | $9.8K | -$4.0M | $5.5M | $4.9M | $22.1M | — |
| FY2023 (FY) | 2023-12-31 | $2.8M | -$30.2M | -$38.9M | -$38.9M | — | — |
3. DARE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs DARE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Dare Bioscience Inc. (NASDAQ: DARE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $0.68 (+0.22% 1D, market cap $13.4M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DARE ranks #523 in composite RQD confidence.
How does DARE compare to BFRI and RKTO in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DARE carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 71.3%, and ROIC of -35.0%. By comparison, BFRI (Biofrontera Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $13.8M) and RKTO (Rocket One Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $12.8M). Among the 5-stock peer group, DARE leads on earnings multiple (N/A) while DARE leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for DARE?
Per DARE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001401914), Dare Bioscience Inc. generated $1.0M in revenue (+10429.4% YoY), -$13.4M in net income, and -$10.3M in free cash flow against $32.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is DARE trading relative to its 50-day, 200-day, and 52-week technical levels?
DARE last traded at $0.68 (+0.22% on volume of 46,862 shares), positioning the stock -9.33% below its 50-day simple moving average ($0.75) and -56.96% below its 200-day simple moving average ($1.58). Across its 52-week range of $0.63 to $3.78, DARE sits at the 1.6% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.77).
DARE Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is DARE stock moving today?
Why DARE Stock advanced +0.22% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.